US Brand: Atripla
Indian (Generic) Brand: Viraday
Manufacturing: Cipla
Active Substance: Tenofovir + Emtricitabine + Efavirenz
Dosage: 300mg + 200mg + 600mg
Form release: bottle 30 tab
Shipping time: 9 – 14 days

Description

Atripla was created in collaboration between Merck, which holds the patent on efavirenz (Sustiva) for sale outside the US and Western Europe, and by Gilead, which holds patents on tenofovir (Viread) and emtricitabine (Emtriva). Atripla applies only to holders of patents, licensing for its production in other countries is not available. Under these conditions, drug price competition does not depend on and is likely to remain stable.

In some countries the licensing of new drug may take several years, especially because of tenofovir has not yet approved for use in many countries. The combination of efavirenz, tenofovir and emtricitabine recommended by the World Health Organization as the preferred first-line therapy, if it is available, as the risk of toxicity of this combination is relatively low.

Images of Medicine.